Circular RNA circDNA2 upregulates CCDC6 expression to promote the progression of gastric cancer via miR-149-5p suppression

Duochen Jin,1,2,3 Keting Huang,1,2,3 Lei Peng,1 Ping Xu,1 Yini Dang,1 Jiakia Yang,1 Meihong Chen,1 Xudong Zhu,1,2 Shuchun Wei,1,2 Jin Yan,1,2 and Guoxin Zhang1,2

1Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing 210029, China; 2First Clinical Medical College of Nanjing Medical University, Nanjing, China

Circular (circ)RNAs are widely involved in gastric cancer (GC) pathogenesis, and coiled-coil domain containing 6 (CCDC6) is a fused partner of multiple oncogenes; however, the underlying mechanisms of how circRNAs regulate CCDC6 expression in the progression and prognosis of GC remain unclear. Here, we discovered the circRNA derived from the DNA2 gene locus (circDNA2) through RNA sequencing. By performing quantitative real-time PCR and fluorescence in situ hybridization (FISH) assays with a human tissue microarray, circDNA2 was found to be highly expressed in GC tissues and associated with lymphatic invasion of GC patients. Knockdown of circDNA2 expression suppressed the proliferation of GC cells by reducing CCDC6 expression. Mechanistically, circDNA2 acted as a microRNA (miR)-149-5p sponge, which was confirmed to target CCDC6 by RNA pulldown and dual-luciferase reporter assays and rescue experiments. Both low miR-149-5p expression and high CCDC6 expression were related to unfavorable prognosis in GC patients. Moreover, GC patients with low miR-149-5p expression had shorter overall survival and a higher risk of chemotherapy resistance than those with high miR-149-5p expression. In summary, circDNA2 contributes to the growth and lymphatic metastasis of GC by upregulating CCDC6 expression by sponging miR-149-5p. The circDNA2/miR-149-5p/CCDC6 axis might be developed as a therapeutic target and prognostic indicator for GC.

INTRODUCTION

Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer-related death worldwide, with an estimated 782,685 GC-related deaths in 2018.1 Early diagnosis is essential for treating GC patients and thereby improving their prognosis.2 However, the early stage of GC lacks specific symptoms, and the diagnosis of GC mainly depends on endoscopy combined with tissue biopsy, imaging examination, and serum tumor marker detection.3 Tissue biopsy is the gold standard method, but this obvious visual change in histopathology is lagging. We hope to identify novel biomarkers closely related to the tumorigenesis of GC that can assist clinicians in the early risk assessment, individualized treatment, and prediction of survival time of GC.

Circular (circ)RNAs are stable and conserved products of the RNA backsplicing process and are also predominant transcripts of diverse human cell types.4,5 circRNAs with covalently closed loop structures are noncoding RNAs (ncRNAs) that facilitate circularization by forming lariat structures or pairing flanking ALU sequences in bordering introns.5,6 circRNAs participate in the pathogenesis of many diseases, including cancers, and have been reported to regulate gene expression at the transcriptional, post-transcriptional, and translational levels.6,9 Current studies have revealed that circRNAs can promote or inhibit GC initiation and progression by sponging microRNAs (miRNAs) through their miRNA-binding sites.10,11 In addition, circRNAs have higher stability and tissue specificity than other ncRNAs, and they are widely distributed in body fluids. Therefore, these molecules may be used as potential GC-related molecular biomarkers or targets for early diagnosis and effective therapy.

Coiled-coil domain containing 6 (CCDC6) was originally recognized as a partner in fusion with the tyrosine kinase rearranged during transfection (RET) receptor from a human papillary thyroid carcinoma (PTC) sample.12 The 65 kDa protein product of the CCDC6 gene is expressed in both the nucleus and cytoplasm of almost all human tissues. To date, CCDC6 has been identified as a partner of various proto-oncogenes in fusions, such as MYC, MLLT3, RARA, ALK, and RUNXI, other than RET in different tumor types, and most of these oncogenes fused to CCDC6 enhance cell proliferation.13

Received 11 November 2020; accepted 26 May 2021; https://doi.org/10.1016/j.omtn.2021.05.021.

These authors contributed equally

Correspondence: Jin Yan, Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing 210029, China.
E-mail: jsy0220@163.com

Correspondence: Guoxin Zhang, Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing 210029, China.
E-mail: guoxinz@njmu.edu.cn
Fusion of the coiled-coil domain of CCDC6 to the tyrosine kinase domain of RET was identified as a novel oncogenic driver in advanced colorectal cancer. Moreover, as a ROS1 fusion protein, CCDC6 promotes oncogenic receptor tyrosine kinase dimerization and activation, which may occur in gastric carcinoma.

At present, some studies have explored the regulation of CCDC6 by a set of ncRNAs. Jia et al. and Leone et al. separately reported that overexpression of miRNA (miR)-146b-5p and miR-130b-3p promoted the development of human thyroid papillary carcinomas and follicular adenomas by both targeting CCDC6. A common G/C polymorphism in pre-miR-146a decreased the amount of mature miR-146a, led to reduced inhibition of CCDC6 gene expression, and genetically predisposed patients to PTC. The miR-19b-3p/CCDC6 axis was found to enhance cell proliferation and the nuclear translocation of β-catenin to promote intrahepatic cholangiocarcinoma progression in vivo.

In the present study, we first investigated the correlation of CCDC6 expression with the clinicopathological characteristics of GC patients and examined the change in CCDC6 expression from the perspective of ncRNAs in GC progression.

RESULTS

circRNA profiling in GC tissues and circDNA2 characterization

We constructed a circRNA profiling database by sequencing ribosomal RNA-depleted total RNA obtained from tumor tissues and pair-matched adjacent normal tissues of 3 GC patients. The bioinformatics analysis pipeline used to identify candidate circRNAs is summarized in Figure 1A. We detected 3,120 circRNAs in the aforementioned 3 pairs of GC tissues that had been reported on the circBase website. The predicted sequence length of 83.62% (2,609/3,120) of the circRNAs was shorter than 1,000 nucleotides (Figure 1B), which is similar to a previously published study. Our RNA sequencing (RNA-seq) data also revealed that 95.96% (2,994/3,120) of the circRNAs were derived from exons (Figure 1C). Twenty-one circRNAs with downregulated expression and ten with upregulated expression in GC tissues were identified as differentially expressed circRNAs by analyzing the cluster heatmap, which shows the expression variations of circRNA transcripts among GC tissues and paired adjacent noncancerous tissues (fold change > 2, p < 0.05; Figure 1D). The raw sequencing data were submitted to the Gene Expression Omnibus database (GSE167512). Then, we further detected the expression level of circDNA2 in 20 pairs of GC tissues and matched adjacent normal tissues via quantitative real-time PCR and found that circDNA2 had a higher expression level in tumor tissues (p < 0.05; Figure 1E). Compared with that in the immortalized normal gastric epithelial cell line GES-1, the expression of circDNA2 in the GC cell lines AGS, SGC-7901, and BGC-823 was considerably increased, with the highest expression of circDNA2 in AGS GC cells, followed by SGC-7901 GC cells (Figure 1F).

circDNA2 is derived from the DNA replication helicase/nuclease 2 (DNA2) gene, which is located at chromosome 10q 21.3, and connects exon 2 to exon 5 of the DNA2 gene (chr10:70218860–70229920) to form a circular structure. The genomic sequence length of circDNA2 is 11,060 nt, and its spliced length is predicted to be 645 nt, as shown by the online website circBase (http://www.circbase.org/). The head-to-tail splicing structure of circDNA2 was confirmed with quantitative real-time PCR products by Sanger sequencing (Figure 2A). The results of quantitative real-time PCR assays showed that compared with that in the absence of RNase R exonuclease, the relative expression of GAPDH in AGS cells decreased by 93.4-fold, linear DNA2 by 45.0-fold, and circDNA2 by 1.4-fold, indicating that the ability of circDNA2 to tolerate RNase R exonuclease digestion was 32 times that of the homologous linear gene DNA2; similar results were obtained in the SGC-7901 GC cells: circDNA2 was 38 times more resistant to digestion induced by RNase R exonuclease than linear DNA2 gene, suggesting that circDNA2 harbors a nonlinear circular structure (Figure 2B). We next examined the stability of circDNA2 with 2 mg/mL actinomycin D, a transcription inhibitor. Quantitative real-time PCR assays showed that the half-life of the circDNA2 transcript exceeded 24 h, while that of the homologous linear gene DNA2 was only ~6 h (Figure 2C), suggesting that highly stable circDNA2 has potential as a diagnostic or prognostic biomarker. Furthermore, we analyzed the subcellular localization of circDNA2 and the expression level in GC tissues. Cytoplasmic and nuclear RNAs of AGS and SGC-7901 cells were separately detected by quantitative real-time PCR, and the results showed that circDNA2 was mainly localized in the cytoplasm of the two cell lines (Figure 2D). In addition, we directly observed the localization of circDNA2 in GC tissue cells and adjacent normal tissue cells by fluorescence in situ hybridization (FISH). We found that the green fluorescence representing the distribution of circDNA2 was located in the cytoplasm of the two types of tissue cells and that the expression of circDNA2 in GC tissue cells was higher than that in normal tissue cells (Figure 2E). In summary, circDNA2 is a highly stable circRNA localized in the cytoplasm that deserves exploration for its relationship with the diagnosis and prognosis of GC.

CCDC6 increased microsatellite instability and led to an unfavorable prognosis in GC patients

We first analyzed the human GC data in the The Cancer Genome Atlas (TCGA) RNA-seq database combined with normal gastric data from the GTEx V8 database and found that CCDC6 expression was significantly increased in GC tissues relative to adjacent normal gastric tissues (Figure 3A; Figure S1). We further detected CCDC6 mRNA expression in 20 GC tissues and paired normal gastric tissues and found that CCDC6 was highly expressed in the tumor tissues (Figure 3B). We continued to explore the correlation of CCDC6 expression level with clinicopathological characteristics or prognosis of GC patients in the TCGA database. As shown in Figure 3C, there was a significantly positive correlation of CCDC6 gene expression levels with the microsatellite instability (MSI) score of the GC patients (p = 0.016, ρ = 0.12, 95% CI 0.02–0.23, n = 374). However, the expression level of CCDC6 was not significantly correlated with the age, sex, pathological stage, tumor size, T classification, N classification, distant metastasis, or pathological grade of the GC patients (Figures S2A–S2H).
The online platform Kaplan-Meier plotter21 was used to estimate the correlation of CCDC6 expression with overall survival (OS) of GC patients. We found shorter OS and survival after chemotherapy in GC patients with high CCDC6 expression (Figures 3D and 3I). Further pathological staging analysis revealed that GC patients with stage II, stage III, or stage IV disease with high CCDC6 expression had a significantly shorter OS than those with low CCDC6 expression (Figures 3E–3H).
miR-149-5p, a potential miRNA that acts as a circDNA2 sponge, may target the CCDC6 gene.

Previous studies have revealed that miRNAs can repress mRNA translation or directly cleave their mRNA targets and thus play pivotal roles in GC occurrence and development. Therefore, we used starBase v.3.0 (http://starbase.sysu.edu.cn/index.php) to verify the potential miRNAs targeting CCDC6 gene 3’ UTR under strict screening conditions. All miRNAs were expressed in at least 4 tumor types with a strict stringency (≥ 5) for the CCDC6 gene, which could be predicted in both microT25 and PITA26 target-predicting programs. Next, given that numerous studies indicate that circRNAs sponge and bind to miRNAs to regulate gene transcription and therefore are involved in...
were colocalized in the cytoplasm (Figure 4I). We subsequently found a mutual expression correlation between circDNA2 and miR-149-5p and found that the two molecules could directly bind to each other. We inserted the constructed circDNA2 fragment downstream of the luciferase reporter gene. The luciferase reporter gene was then cotransfected with miR-149-5p mimic or inhibitor and luciferase reporter vectors including wild-type (WT) or mutant-type (Mut) circDNA2 3′ UTR (Figure 5D). Consequently, the luciferase activity of the AGS cells with cotransfection of WT circDNA2 3′ UTR and miR-149-5p mimic was notably decreased (p < 0.001; Figure 5E) compared with that of the AGS cells with cotransfection of WT circDNA2 3′ UTR and NC group (p > 0.05), but the luciferase activity of the group cotransfected with WT circDNA2 3′ UTR and miR-149-5p inhibitor was strongly increased compared with that of the inhibitor NC group (p < 0.001; Figure 5F). Interestingly, the luciferase activity of the group with cotransfection of Mut circDNA2 3′ UTR and miR-149-5p inhibitor was not different from that of the inhibitor NC group (p > 0.05), but the luciferase activity of the group cotransfected with Mut circDNA2 3′ UTR and miR-149-5p mimic was also decreased compared with that of the mimic NC group (p < 0.001), which might be due to the residual binding sites of Mut circDNA2 3′ UTR and miR-149-5p.

Knockdown of circDNA2 reduced CCDC6 expression and inhibited the proliferation of GC cells in vitro

Before exploring the regulatory effects of circDNA2 on CCDC6, we first designed an overexpression vector and a small interfering miR-149-5p and their correlation in a human tissue microarray with 80 pairs of matched GC tissues. Since the tissues at 2 sites were missing during the FISH assays (D13 and J3), 78 pairs of GC matched tissues were included for further investigation (Figure 4K). We also discovered that circDNA2 expression was relatively high whereas miR-149-5p expression was low in GAC tissues compared with normal tissues adjacent to the tumor, which were negatively correlated with each other (r = −0.1925, p < 0.05; Figures 4L and 4M).

miR-149-5p was confirmed to target the CCDC6 gene

We first found that compared with that in the GES-1 cell line, miR-149-5p expression was low in the AGS and SGC-7901 GC cell lines, while CCDC6 expression was high in GC cells, as shown by quantitative real-time PCR detection, and miR-149-5p expression in AGS cells was relatively lower than that in SGC-7901 cells (Figure 5A). Therefore, miR-149-5p mimic (60 μM) was transfected into AGS cells with high circDNA2 expression, and miR-149-5p inhibitor (80 μM) was transfected into SGC-7901 cells with low circDNA2 expression. Quantitative real-time PCR and western blot assays indicated that miR-149-5p expression increased and CCDC6 expression decreased 48 h after AGS cells were transfected with miR-149-5p mimic (p < 0.001, p < 0.01; Figure 5B), while decreased miR-149-5p expression accompanied by increased CCDC6 expression was detected in the SGC-7901 cells transfected with miR-149-5p inhibitor (p < 0.001, p < 0.001; Figure 5C). Furthermore, AGS and SGC-7901 cells were cotransfected with miR-149-5p mimic or inhibitor and luciferase reporter vectors including wild-type (WT) or mutant-type (Mut) CCDC6 3′ UTR (Figure 5D). Consequently, the luciferase activity of the AGS cells with cotransfection of WT CCDC6 3′ UTR and miR-149-5p mimic was notably decreased (p < 0.001; Figure 5E) compared with that of the mimic NC group, but the luciferase activity of the SGC-7901 cells with cotransfection of Mut CCDC6 3′ UTR and miR-149-5p inhibitor was strongly increased compared with that of the inhibitor NC group (p < 0.001; Figure 5F). Interestingly, the luciferase activity of the group with cotransfection of Mut CCDC6 3′ UTR and miR-149-5p inhibitor was not different from that of the inhibitor NC group (p > 0.05), but the luciferase activity of the group cotransfected with Mut CCDC6 3′ UTR and miR-149-5p mimic was also decreased compared with that of the mimic NC group (p < 0.001), which might be due to the residual binding sites of Mut CCDC6 3′ UTR and miR-149-5p.

Knockdown of circDNA2 reduced CCDC6 expression and inhibited the proliferation of GC cells in vitro

Before exploring the regulatory effects of circDNA2 on CCDC6, we first designed an overexpression vector and a small interfering miR-149-5p and their correlation in a human tissue microarray with 80 pairs of matched GC tissues. Since the tissues at 2 sites were missing during the FISH assays (D13 and J3), 78 pairs of GC matched tissues were included for further investigation (Figure 4K). We also discovered that circDNA2 expression was relatively high whereas miR-149-5p expression was low in GAC tissues compared with normal tissues adjacent to the tumor, which were negatively correlated with each other (r = −0.1925, p < 0.05; Figures 4L and 4M).

miR-149-5p was confirmed to target the CCDC6 gene

We first found that compared with that in the GES-1 cell line, miR-149-5p expression was low in the AGS and SGC-7901 GC cell lines, while CCDC6 expression was high in GC cells, as shown by quantitative real-time PCR detection, and miR-149-5p expression in AGS cells was relatively lower than that in SGC-7901 cells (Figure 5A). Therefore, miR-149-5p mimic (60 μM) was transfected into AGS cells with high circDNA2 expression, and miR-149-5p inhibitor (80 μM) was transfected into SGC-7901 cells with low circDNA2 expression. Quantitative real-time PCR and western blot assays indicated that miR-149-5p expression increased and CCDC6 expression decreased 48 h after AGS cells were transfected with miR-149-5p mimic (p < 0.001, p < 0.01; Figure 5B), while decreased miR-149-5p expression accompanied by increased CCDC6 expression was detected in the SGC-7901 cells transfected with miR-149-5p inhibitor (p < 0.001, p < 0.001; Figure 5C). Furthermore, AGS and SGC-7901 cells were cotransfected with miR-149-5p mimic or inhibitor and luciferase reporter vectors including wild-type (WT) or mutant-type (Mut) CCDC6 3′ UTR (Figure 5D). Consequently, the luciferase activity of the AGS cells with cotransfection of WT CCDC6 3′ UTR and miR-149-5p mimic was notably decreased (p < 0.001; Figure 5E) compared with that of the mimic NC group, but the luciferase activity of the SGC-7901 cells with cotransfection of Mut CCDC6 3′ UTR and miR-149-5p inhibitor was strongly increased compared with that of the inhibitor NC group (p < 0.001; Figure 5F). Interestingly, the luciferase activity of the group with cotransfection of Mut CCDC6 3′ UTR and miR-149-5p inhibitor was not different from that of the inhibitor NC group (p > 0.05), but the luciferase activity of the group cotransfected with Mut CCDC6 3′ UTR and miR-149-5p mimic was also decreased compared with that of the mimic NC group (p < 0.001), which might be due to the residual binding sites of Mut CCDC6 3′ UTR and miR-149-5p.
Figure 4. Identification of miR-149-5p as a potential miRNA for circDNA2 sponging

(A) We screened out hsa-miR-149-5p and hsa-miR-375, which can target the CCDC6 gene 3' UTR and be sponged by circDNA2. (B) Predicted consequential pairing of miRNAs with CCDC6 gene in stomach adenocarcinoma tissues (372 samples) (starBase v3.0 project).

| miRNAs       | Regression | Coefficient | P-value |
|--------------|------------|-------------|---------|
| hsa-miR-149-5p | y = 0.1124x + 3.8927 | -0.255 | < 0.0001 |
| hsa-miR-375   | y = -0.0223x + 4.3039   | -0.051 | 0.117 |

(C) The relative expression levels of miR-149-5p in GC tissues and adjacent normal tissues were analyzed using TCGA RNA-seq data. (D) Pearson correlation analyses between miR-149-5p and CCDC6 expression were performed for GC tissues and adjacent normal tissues using TCGA data. (E) The predicted binding site of circDNA2 and miR-149-5p. (F) Dual-luciferase reporter assays were used to determine whether there was a direct binding site between circDNA2 and miR-149-5p. (G and H) Coprecipitation and detection of circDNA2 and miR-149-5p in AGS and SGC-7901 cell lysates with RNA pulldown and quantitative real-time PCR assays. (I) FISH analysis revealed that circDNA2 colocalized with miR-149-5p in the cytoplasm of GC tissue cells. Scale bars, 50 μm. (J) Mutual regulation of circDNA2 and miR-149-5p indicated by quantitative real-time PCR. (K) RNA FISH assays for a human GC tissue microarray. (L and M) The relative expression levels and correlation of circDNA2 and miR-149-5p in GC and pair-matched adjacent normal tissues. The data are represented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
RNA (siRNA) against the backspliced sequence of circDNA2 (Figure 6A) and detected their transfection efficiency in AGS and SGC-7901 GC cells (Figure 6B). We further determined that the CCDC6 expression level in the circDNA2 transfection group was significantly strengthened compared with that in the NC group, while knockdown of circDNA2 with si-circDNA2 significantly decreased the level of CCDC6 compared with that in the si-NC transfection group (Figure 6C). Since CCDC6 was previously reported to promote tumor cell proliferation29–31 and circDNA2 might enhance CCDC6 expression by sponging miR-149-5p based on our aforementioned results, we therefore investigated whether circDNA2 affected GC cell proliferation by performing functional assays. As shown in Figures 6D–6F, the GC cell proliferative capacity was comprehensively evaluated by CCK-8, 5-ethyl-2'-deoxyuridine (EdU), and colony formation assays. We found that AGS cell proliferation was inhibited by transfection of si-circDNA2, while circDNA2 overexpression enhanced SGC-7901 cell proliferation. Moreover, miR-149-5p knockdown recovered si-circDNA2-induced inhibition of AGS cell proliferation, and cotransfection of miR-149-5p mimics reversed the cell proliferation caused by circDNA2 in SGC-7901 cells.

Figure 5. miR-149-5p was validated to target CCDC6 gene
(A) The relative expression levels of miR-149-5p and CCDC6 in GES-1 cells and AGS and SGC-7901 GC cells by quantitative real-time PCR detection. (B and C) The relative expression levels of miR-149-5p and CCDC6 in AGS or SGC-7901 GC cells transfected with miR-149-5p mimic or inhibitor for 48 h by quantitative real-time PCR and western blot detection. (D) Schematic diagram of the binding sites of WT or Mut CCDC6 3’ UTR and miR-149-5p. (E) The luciferase activity of AGS cells with cotransfection of WT or Mut CCDC6 3’ UTR with miR-149-5p mimic. (F) The luciferase activity of SGC-7901 cells with cotransfection of WT or Mut CCDC6 3’ UTR with miR-149-5p inhibitor. The data are represented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.

circDNA2 and miR-149-5p expression were associated with lymphatic invasion and prognosis of GC patients, respectively
We first evaluated whether circDNA2 and miR-149-5p expression were correlated with the clinicopathological characteristics and prognosis of 78 GC patients. circDNA2 expression was positively associated with lymph node metastasis in the GC patients (N0 + N1 versus N2 + N3, p = 0.0124). In addition, circDNA2 and miR-149-5p were not significantly correlated with other clinical parameters of the GC patients (p > 0.05; Figures 7A and 7B; Tables S1 and S2). The expression levels of circDNA2 and miR-149-5p in GC tissues and adjacent normal tissues were divided into two groups, high expression and low expression, and binary logistic regression analysis was used to construct a risk score for the incidence of GC (Figure 7C). The area under the curve (AUC) for circDNA2 combined with miR-149-5p to assess the GC occurrence rate was 0.7301 (sensitivity 61.5%, specificity 79.5%), suggesting that circDNA2 and miR-149-5p may be biomarkers for predicting GC occurrence.

Furthermore, we did not find that the circDNA2 expression level was significantly correlated with OS or survival after chemotherapy in the GC patients (Figures S3A–S3D and S3G). GC patients with low
Figure 6. Knockdown of circDNA2 reduced CCDC6 expression and inhibited the proliferation of GC cells in vitro
(A) Schematic diagram of the siRNA sequence for the backsplicing junction site of circDNA2. (B) The transfection efficiency was detected by quantitative real-time PCR assays 48 h after transfection of the overexpression plasmid or the siRNA of circDNA2. (C) The CCDC6 level was determined by quantitative real-time PCR assays in the circDNA2 or si-circDNA2 transfection group relative to the corresponding NC transfection group. (D–F) Cell proliferation of AGS and SGC-7901 GC cells transfected with circDNA2 knockdown or overexpression was comprehensively evaluated by CCK-8, EdU, and colony formation experiments; scale bar, 50 μm. The data are represented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
miR-149-5p expression had a shorter OS than GC patients with high miR-149-5p expression (Figure 7D). Further pathological staging analysis revealed that GC patients with stage III disease with low miR-149-5p expression had significantly poorer OS and survival after chemotherapy (Figures 7E and 7F; Figures S3E, S3F, and S3H).

DISCUSSION

For the current study, we aimed to investigate whether CCDC6 expression in GC tissues and cell lines was regulated by ncRNAs, similar to the other tumor types mentioned above. First, we filtered out highly expressed circDNA2 in GC tissues from our RNA-seq results and further determined that circDNA2 existed stably in the cytoplasm because of its circular structure. Second, we discovered that circDNA2 knockdown obstructed proliferation and CCDC6 expression in GC cells, whereas miR-149-5p inhibition reversed the effects of circDNA2 knockdown and promoted GC cell proliferation. Additionally, GC patients with high expression of circDNA2 often had lymph node metastasis, indicating the progression of GC. Although we found that a consistent trend was observed in CCDC6 expression when the expression of circDNA2 was inhibited or promoted in GC cells (Figure 6C), circDNA2 in the cytoplasm did not directly affect the transcriptional process of the CCDC6 gene.

Considering that circRNAs act as miRNA sponges to play a post-transcriptional role in a variety of tumors and sequestering a miRNA may diminish its repressive effects on its target genes, miR-149-5p targeting of the CCDC6 gene was confirmed through bioinformatics analyses, which showed that this miRNA was also sponged by circDNA2. We next demonstrated that miR-149-5p directly bound to CCDC6 or circDNA2 via dual-luciferase reporter gene assays and functional gain and loss experiments. Several studies independently reported that miR-149-5p has a tumor-suppressive role in GC, which was consistent with our findings. In our study, the AUC for a single miR-149-5p expression level to predict the risk of GC occurrence reached 0.7102, indicating that miR-149-5p has potential as a biomarker for GC diagnosis. In addition, low expression of miR-149-5p might indicate a potentially poor prognosis for GC patients with shortened OS and survival after chemotherapy.

Previous studies on CCDC6-related oncology have focused on the thyroid, liver, and lung. CCDC6 was identified as the target gene of...
miR-146-5p in PTC,16 and miR-19b-3p in intrahepatic cholangiocarcinoma (ICC)19 and inhibited cell proliferation and epithelial-mesenchymal transition and facilitated cell apoptosis. However, the fusion of the RET kinase with its partner protein CCDC6 led to cell proliferation by activating downstream intracellular signaling and enhancing gene transcription in non-small cell lung cancer.20,21 For instance, LC-2/ad cells are a human lung adenocarcinoma cell line endogenously expressing the CCDC6-RET fusion gene, which contributes to ERK1/2 phosphorylation and cell proliferation in a xenograft model.22 In this study, we explored the expression of CCDC6 in GC patients and its association with the clinicopathological characteristics and prognosis of GC patients, which suggested that CCDC6 was highly expressed in GC tissues relative to adjacent normal gastric tissues, and GC patients with high CCDC6 expression possessed high levels of MSI and shortened OS and survival after chemotherapy. Our results might help elucidate the roles of CCDC6 in the pathogenesis of GC.

Our RNA-seq data revealed that the predicted sequence length of 83.62% of the circRNAs was <1,000 nucleotides (Figure 1B), which was similar to previously published literature.23 However, we found that 95.96% of the circRNAs were derived from exons (Figure 1C), while Zhang X et al. reported that 56.57% of circRNAs were derived from introns. This difference in the gene distribution of circRNAs might be because the abovementioned literature analyzed the total circRNAs detected (n = 35,156), while we analyzed the circRNAs that could be annotated on the circBase website (n = 3,120).

In summary, circDNA2 and miR-149-5p both have potential to be developed as biomarkers for the diagnosis of GC. The advantage of circDNA2 as a biomarker is that it has a stable loop structure, while the advantage of miR-149-5p is that it can also predict OS and survival after chemotherapy in GC patients. In this study, we also revealed that CCDC6 is a novel target in GC tumorigenesis that is associated with MSI and unfavorable prognosis of GC patients and should be further explored to elucidate its underlying mechanisms.

MATERIALS AND METHODS

Patient samples

The clinicopathological data of GC cases and the relative expression levels of the CCDC6 gene and miRNAs, including hsa-miR-149-5p, hsa-miR-654-3p, and hsa-miR-375, in GC tissues were obtained from the TCGA 2015 RNA-seq database (http://xena.ucsc.edu/getting-started/). A human tissue microarray containing 80 pairs of GC tissues and matched adjacent normal gastric tissues (Cat No. STC1602) was acquired from Shanghai Superbiotek Pharmaceutical Technology Co., Ltd. (Shanghai, China). Twenty pairs of GC and adjacent normal gastric tissues were immediately collected after surgical resection from the First Affiliated Hospital of Nanjing Medical University in 2019 and used to compare the relative expression of CCDC6 between tumor and adjacent tissues. The study protocols were approved by the Ethical Committee of the First Affiliated Hospital of Nanjing Medical University.

RNA sequencing

Three pairs of GC tissues were randomly selected for RNA-seq from the abovementioned 20 pairs of GC tissues collected by our center. Relevant clinicopathological details of the 3 selected GC patients are listed in Table S4. After the ribosomal RNAs were removed from total RNA with Ribo-Zero rRNA Removal Kits (Illumina, USA), RNA-seq libraries were constructed by using a TruSeq Stranded Total RNA Library Prep Kit (Illumina, USA) and further controlled for quality and quantified with the BioAnalyzer 2100 system (Agilent Technologies, USA). Ten pM libraries were denatured as single-stranded DNA molecules, captured on Illumina flow cells, amplified in situ as clusters, and finally sequenced for 150 cycles on an Illumina HiSeq 4000 Sequencer. Q30 was used for quality control of paired-end reads, and Cutadapt software (v.1.9.3) was used for trimming the 3′ adaptor and removing low-quality reads. Finally, circRNAs were analyzed with high-quality trimmed reads.

Identification of differentially expressed circRNAs

RNA-seq reads were aligned to the reference genome UCSC hg19 with Bowtie2 software, and circRNAs were detected and identified with find_circ software. The identified circRNAs were annotated with circBase and circ2Traits databases. Raw junction reads for all samples were normalized by total read number and log2 transformed. Differentially expressed circRNAs (fold-change cutoff > 2, p < 0.05) were identified by t tests between GC tissues and adjacent normal tissues.

Cell culture

The human normal gastric epithelial cell line GES-1 and GC cell lines AGS, SGC-7901, and BGC-823 were maintained by the Institute of Digestive Diseases of the First Affiliated Hospital of Nanjing Medical University. All cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin solution (Beyotime, Haimen, China) and placed in a humidified incubator containing 5% CO2 at 37°C.

RNA extraction and quantitative real-time PCR

Total RNA of GC cells or tissues was extracted by TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The minimum number of GC cells required for total RNA extraction was ~2.5 × 10⁷ cells. NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific, Waltham, MA, USA) were used to separate cytoplasmic and nuclear RNA fractions. Reverse transcription of mRNAs and circRNAs was performed with SuperScript II (TaKaRa, Dalian, China), and quantitative real-time PCR was performed with a SYBR Green Master Mix kit (TaKaRa). Reverse transcription for miRNAs was implemented with a PrimeScript RT reagent Kit (TaKaRa) following the manufacturer’s instructions. Each sample was reverse transcribed with 1,000 ng of RNA. Sequences of the PCR primers are listed in Table S3. Bulge-loop miRNA quantitative real-time PCR Primer Sets (one RT primer and a pair of qPCR primers) specific for miR-149-5p were designed by RiboBio (Guangzhou, China). GAPDH was used as the internal reference for mRNA and circRNA. The miRNA level was normalized to the RNU6-I level.
RNase R and actinomycin D treatment
Total RNA was digested by 3 U/mg RNase R exonuclease (Epicenter Technologies, Madison, WI, USA) for 20 min at 37°C to degrade linear RNA. Total RNA was harvested after addition of 2 mg/ml actinomycin D (Sigma-Aldrich, St. Louis, MO, USA) to inhibit transcription. Reverse transcription and quantitative real-time PCR were then performed on RNase R- or actinomycin D-treated RNA.

RNA fluorescence in situ hybridization
Both GC and adjacent normal gastric tissues fixed in 4% paraformaldehyde were embedded in paraffin and then sectioned. The sections were gradually dehydrated in xylene and 100%, 85%, and 75% ethanol for subsequent FISH experiments. circDNA2 probe sequence: 5'-DIG-CTTTCTCTGAAATAGAGAGAGCTGCATCT-DIG-3'; miR-149-5p probe sequence: 5'-CY3-GGAGTGAAGACACGGAGCCAGA-3'. The sections were hybridized with 6 ng/μL of digoxigenin (DIG)-labeled circDNA2 probe overnight at 37°C and then washed with saline sodium citrate (SSC) and 50% formamide to remove hybridization buffer. The sections were incubated with anti-DIG-horseradish peroxidase (HRP) (Jackson ImmunoResearch, Inc., West Grove, PA, USA) at 4°C for 50 min and then washed three times in PBS for 5 min each time. Subsequently, the sections were incubated with fluorescein isothiocyanate (FITC)-TSA (Servicebio, Wuhan, China) to amplify the fluorescent signal. The miR-149-5p probe (8 ng/μL) was also added to the slices for hybridization at 37°C overnight to observe whether circDNA2 and miR-149-5p were colocalized in the cytoplasm.

Luciferase reporter assay
The 3' UTR sequence of circDNA2 was cloned into a pGL3 promoter. AGS and SGC-7901 cells were seeded in 24-well plates for 24 h and then cotransfected with miR-149-5p mimic or inhibitor and NC with the WT or Mut 3' UTR of circDNA2. In addition, WT or Mut CCDC6 3' UTR was cotransfected with miR-149-5p mimic or inhibitor in AGS or SGC-7901 cells. After 48 h of transfection, firefly luciferase activities were detected with a dual-luciferase reporter kit (Promega, Madison, WI, USA) and further normalized to Renilla luciferase activities.

circRNA pulldown assay
The biotinylated circDNA2 probe was specifically designed to bind to the junction region of circDNA2 (biotin-labeled circDNA2 probe: 5'-CCACTTTCTCTGAAATAGAGAGGCTGCATCTG-3'), while the scramble 22 nt oligo probe was used as a control (biotin-labeled negative probe: 5'-GTGTAACAGTCTATACGCCCA-3'). Approximately 6 × 10⁷ cells were harvested and lysed. The circDNA2-specific probe was incubated with streptavidin magnetic beads (Thermo Fisher, USA) at 4°C overnight to generate probe-coated beads. The cell lysates were incubated with probe-coated beads at room temperature for 1 h. The beads were washed, and the bound miRNAs in the pulldown samples were extracted with TRIzol reagent and further evaluated by quantitative real-time PCR assays.

Plasmid and oligonucleotide transfection
Plasmid and siRNA vectors targeting circDNA2 and miR-149-5p mimic or inhibitor were commercially obtained from GenePharma (Shanghai, China). si-DNA2 sequence: 5'-GCTCTCTCTATTTCA GAAGAA-3'. The human GC cell lines AGS and SGC-7901 were seeded in 6-well plates to reach 80%-90% confluence and then transfected with circDNA2 overexpression plasmid, si-circDNA2, and miR-149-5p mimic or inhibitor accompanied by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for 48 h.

Western blot
Protein extracts were boiled with loading buffer and then separated by electrophoresis on 10% SDS-PAGE gels. After transfer onto a polyvinylidene fluoride (PVDF) membrane, separated protein bands were blocked with bovine serum albumin (BSA) for 1 h. The PVDF membranes were hybridized with the primary antibodies overnight at 4°C and then immunoblotted with a corresponding HRP-labeled secondary antibody for 1 h at room temperature. The primary antibodies against CCDC6 (cat. 13717-1-AP, Proteintech, Wuhan, China) and GAPDH (cat. AF5009, Beyotime, Shanghai, China) were diluted according to the recommended ratio, while the secondary antibodies were diluted at a ratio of 1:10,000. Blot signals were visualized with HRP substrate (WBKL0100, Millipore, USA) and captured by a Bio-Rad ChemiDoc XRS+ imaging system. The band images were quantified by a densitometry with ImageJ software, followed by normalization to the loading control GAPDH.

CCK-8 assay
The proliferative activities of AGS and SGC-7901 GC cells were identified by a Cell Counting Kit-8 assay (Dojindo Laboratories, Kumamoto, Japan). Briefly, GC cells were plated in 96-well plates (3,000 cells per well) and incubated with 10 μL of CCK-8 solution per well for 1 h on days 1, 2, 3, and 4. The absorbance of the test wells at 450 nm was measured for analysis.

Colony formation assay
AGS and SGC-7901 GC cells were seeded in 6-well plates (800 cells per well). After incubation at 37°C for 2 weeks, the cell colonies were fixed with 4% paraformaldehyde for 20 min and then stained with 0.1% crystal violet for 20 min. All plates were photographed, and the cell colonies were counted for analysis.

EdU assay
The proliferation of the treated AGS and SGC-7901 GC cells was monitored by an EdU Cell Proliferation Kit (RiboBio, Guangzhou, China). GC cells were seeded in 96-well plates at a density of 1 × 10⁴ cells per well overnight. EdU solution (50 μM) was added to each well of the test plate and incubated with cells for 2 h. The GC cells were then fixed with 4% formaldehyde for 30 min and then incubated with 0.1% crystal violet for 20 min. All plates were photographed, and the cell colonies were counted for analysis.
subsequently permeabilized with 0.5% Triton X-100 for 10 min. Apollo dye solution (200 µl) and Hoechst 33342 (200 µl) were added to stain the EdU-stained cells and the nucleic acids in the cells, respectively. Images were captured to calculate the percentage of EdU-positive GC cells.

**Statistical analysis**

IBM SPSS Statistics 23.0 and GraphPad Prism 8.0 software were used for statistical analyses. Student’s t test or chi-square test was applied to compare two groups. Comparisons of paired samples were performed by paired t test analysis. Pearson’s correlation coefficient was calculated to evaluate the correlations. OS curves were obtained from the Kaplan-Meier plotter with a log-rank p value. Spearman’s correlation analysis was used to describe the correlation between two quantitative variables without a normal distribution with R 4.0.3 software. In this study, we revealed the correlation of CCDC6 gene expression levels with the MSI score of GC patients. Cell experiments were performed in triplicate, and all results are presented as the mean ± the standard error of the mean. p < 0.05 was considered significant.

**SUPPLEMENTAL INFORMATION**

Supplemental information can be found online at https://doi.org/10.1016/j.omtn.2021.05.021.

**ACKNOWLEDGMENTS**

This study was supported in part by the National Natural Science Foundation of China (no. 81770561 and no. 81970499) and the Jiangsu Province Leading Talents and Innovation Team (CXTDA2017033).

**AUTHOR CONTRIBUTIONS**

D. Jin and K. Huang conducted the experiments and wrote the manuscript; L. Peng, P. Xu, and Y. Dang designed the experiments; J. Yang designed the primers; M. Chen, X. Zhu, and S. Wei collected the human tissue samples; J. Yan and G. Zhang revised the manuscript and designed the primers; M. Chen, X. Zhu, and S. Wei collected the human tissue samples; J. Yan and G. Zhang revised the manuscript and provided experimental funding.

**DECLARATION OF INTERESTS**

The authors declare no competing interests.

**REFERENCES**

1. Bray, F., Ferlay, I., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424.
2. Chiurillo, M.A. (2015). Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review. World J. Exp. Med. 5, 84–102.
3. Ajani, J.A., Bentrem, D.J., Besh, S., D’Amico, T.A., Das, P., Denlinger, C., Fakhii, M.G., Fuchs, C.S., Gerdes, H., Glasgow, R.E., et al.; National Comprehensive Cancer Network (2013). Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J. Natl. Compr. Canc. Netw. 11, 531–546.
4. Salzman, J., Gawad, C., Wang, P.L., Lacayo, N., and Brown, P.O. (2012). Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS ONE 7, e30733.
5. Li, R., Jiang, J., Shi, H., Qian, H., Zhang, X., and Xu, W. (2020). CircRNA: a rising star in gastric cancer. Cell. Mol. Life Sci. 77, 1661–1680.
6. Sanger, H.L., Klotz, G., Riesner, D., Gross, H.J., and Kleinschmidt, A.K. (1976). Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc. Natl. Acad. Sci. USA 73, 3852–3856.
7. Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, S.D., Gregersen, L.H., Munschauer, M., et al. (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333–338.
8. Zhao, Y., Alexandrov, P.N., Jaber, V., and Lukiw, W.J. (2016). Deficiency in the Ubiquitin-Conjugating Enzyme UBE2A in Alzheimer’s Disease (AD) is Linked to Deficits in a Natural Circular miRNA-7 Sponge (circRNA; cirR-7). Genes (Basel) 7, 116.
9. Zhang, M., Huang, N., Yang, X., Luo, J., Yan, S., Xiao, F., Chen, W., Gao, X., Zhao, K., Zhou, H., et al. (2018). A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene 37, 1805–1814.
10. Zhang, J., Liu, H., Hou, L., Wang, G., Zhang, R., Huang, Y., Chen, X., and Zhu, J. (2017). Circular RNA LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol. Cancer 16, 151.
11. Chen, Y., Yang, F., Fang, E., Xiao, W., Mei, H., Li, H., Li, D., Song, H., Wang, J., Hong, M., et al. (2019). Circular RNA circAGO2 drives cancer progression through facilitating HuR-repressed functions of AGO2-miRNA complexes. Cell Death Differ. 26, 1346–1364.
12. Fusco, A., Grieco, M., Santoro, M., Berlingieri, M.T., Piotto, S., Pierrot, M.A., Della Porta, G., and Vecchio, G. (1987). A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 328, 170–172.
13. Cerrato, A., Merolla, F., Morra, F., and Celetti, A. (2018). CCDC6: the identity of a protein known to be partner in fusion. Int. J. Cancer 142, 1300–1308.
14. Le Rolle, A.F., Klempner, S.J., Garrett, C.R., Seery, T., Sanford, E.M., Balusubramanian, S., Ross, J.S., Stephens, P.J., Miller, V.A., Ali, S.M., and Chiu, V.K. (2015). Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget 6, 28929–28937.
15. Roskoski, R., Jr. (2017). ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacol. Res. 121, 202–212.
16. Jia, M., Shi, Y., Li, Z., Lu, X., and Wang, J. (2019). MicroRNA-146b-5p as an oncomiR promotes papillary thyroid carcinoma development by targeting CCDC6. Cancer Lett. 443, 145–156.
17. Leone, V., Langella, C., Esposito, F., De Martino, M., Decausse-Petrucci, M., Chiapetta, G., Bianco, A., and Fusco, A. (2015). miR-150-3p Upregulation Contributes to the Development of Thyroid Adenomas Targeting CCDC6 Gene. Eur. Thyroid J. 4, 213–221.
18. Jazdzewski, K., Murray, M., Franssila, K., Jarzab, B., Schoenberg, D.R., and de la Chapelle, A. (2008). Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinomas. Proc. Natl. Acad. Sci. USA 105, 7269–7274.
19. Tang, Y., Yang, J., Wang, Y., Tang, Z., Liu, S., and Tang, Y. (2020). MiR-19b-3p facilitates the proliferation and epithelial-mesenchymal transition, and inhibits the apoptosis of intrahepatic cholangiocarcinoma by suppressing coiled-coil domain containing 6. Arch. Biochem. Biophys. 686, 108367.
20. Zhang, X., Wang, S., Wang, H., Cao, J., Huang, X., Chen, Z., Xu, P., Sun, G., Xu, J., Lv, J., and Xu, Z. (2019). Circular RNA circNRP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. Mol. Cancer 18, 20.
21. Nagy, Á., Lánzczky, A., Menyhárt, O., and Győryf, B. (2018). Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci. Rep. 8, 9227.
22. Shah, M.Y., Ferrajoli, A., Sood, A.K., Lopez-Berestein, G., and Calin, G.A. (2016). microRNA Therapeutics in Cancer - An Emerging Concept. Ebiomedicine 12, 34–42.
23. Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297.
24. Li, J.H., Liu, S., Zhou, H., Qu, L.H., and Yang, J.H. (2014). starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42, D92–D97.
25. Paraskevopoulou, M.D., Georgakilas, G., Kostoulas, N., Vlachos, I.S., Vergoulis, T., Reczko, M., Filipidis, C., Dalamagas, T., and Hatzigeorgiou, A.G. (2013). DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 41, W169, W73.

26. Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., and Segal, E. (2007). The role of site accessibility in miRNA target recognition. Nat. Genet. 39, 1278–1284.

27. Qu, S., Yang, X., Li, X., Wang, J., Gao, Y., Shang, R., Sun, W., Dou, K., and Li, H. (2015). Circular RNA: A new star of noncoding RNAs. Cancer Lett. 365, 141–148.

28. Dudekula, D.B., Panda, A.C., Grammatikakis, I., De, S., Abdelmohsen, K., and Gorsenia, M. (2016). CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 13, 34–42.

29. O’Leary, C., Xu, W., Pavlakis, N., Richard, D., and O’Byrne, K. (2019). Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer. Cancers (Basel) 11, 620.

30. Stinchcombe, T.E. (2020). Current management of RET rearranged non-small cell lung cancer. Ther. Adv. Med. Oncol. 12, 1758835920928634.

31. Suzuki, M., Makinoshima, H., Matsumoto, S., Suzuki, A., Mimaki, S., Matsushima, K., Yoh, K., Goto, K., Suzuki, Y., Ishii, G., et al. (2013). Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer Sci. 104, 896–903.

32. Lin, W., Liu, H., Tang, Y., Wei, Y., Wei, W., Zhang, L., and Chen, J. (2021). The development and controversy of competitive endogenous RNA hypothesis in non-coding genes. Mol. Cell. Biochem. 476, 109–123.

33. Smillie, C.L., Sirey, T., and Ponting, C.P. (2018). Complexities of post-transcriptional regulation and the modeling of cRNA crosstalk. Crit. Rev. Biochem. Mol. Biol. 53, 231–245.

34. Hui, C., Tian, L., and He, X. (2020). Circular RNA circNHSL1 contributes to gastric cancer progression through the miR-149-5p/YWHAZ axis. Cancer Manag. Res. 12, 7117–7130.

35. Wang, Z., Liu, X., Liu, X., and Niu, D. (2020). Long Non-Coding RNA BLACAT1 Promotes the Tumorigenesis of Gastric Cancer by Sponging microRNA-149-5p and Targeting KIF2A. Cancer Manag. Res. 12, 6629–6640.